149 related articles for article (PubMed ID: 35545568)
1. [Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis].
Huang CY; Liu YM; Liu H; Xu B; Yan HP; Zhang HP; Liao HY; Zhang XD; Zhao J; Li WJ; Duan ZP
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):419-425. PubMed ID: 35545568
[No Abstract] [Full Text] [Related]
2. Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis.
Zhu YJ; Li J; Liu YG; Jiang Y; Cheng XJ; Han X; Wang CY; Li J
World J Gastroenterol; 2023 Sep; 29(34):5075-5081. PubMed ID: 37753365
[TBL] [Abstract][Full Text] [Related]
3. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
Huang C; Han W; Wang C; Liu Y; Chen Y; Duan Z
Dis Markers; 2019; 2019():9121207. PubMed ID: 31737133
[TBL] [Abstract][Full Text] [Related]
4. [Differential characteristics of AMA-M2 autoantibody in primary biliary cirrhosis and non-PBC patients].
Sun L; Wang Y; Liu Y; Zhao Y; Zhang X; Wang Y; Zhao D; Zhang H; Ma Y
Zhonghua Gan Zang Bing Za Zhi; 2015 May; 23(5):343-9. PubMed ID: 26192239
[TBL] [Abstract][Full Text] [Related]
5. [An analysis of the serological characteristics of anti-mitochondrial M2 subtype in patients with drug-induced liver injury and primary biliary cholangitis].
Sun LM; Yan HP; Lou JL; Wang Y; Zhao Y; Yu YH; Zhang HP; Liu YM
Zhonghua Gan Zang Bing Za Zhi; 2019 Apr; 27(4):298-303. PubMed ID: 31082342
[No Abstract] [Full Text] [Related]
6. [Clinical features of patients with primary biliary cirrhosis and anti-SP100 autoantibody positivity].
Tang YM; Bao WM; You LY; Jiang HJ; Yang JH
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):359-62. PubMed ID: 24025137
[TBL] [Abstract][Full Text] [Related]
7. [Baseline analysis of refractory primary biliary cirrhosis].
Wang L; Kong F; Zhang X; Xu D; Hu ZJ; Li YZ; Zhang FC
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2918-20. PubMed ID: 23328240
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance of AMA-M2, anti-gp210 and anti-sp100 antibody levels in primary biliary cholangitis: When detected by multiplex bead-based flow fluorescent immunoassay.
Wang Z; Li Y; Ren L; Li Y; Xu T; Li W; Gao W; Sun G; Liu M
Immun Inflamm Dis; 2024 Jan; 12(1):e1161. PubMed ID: 38270327
[TBL] [Abstract][Full Text] [Related]
9. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
Wang X; Yang Z; Ran Y; Li L; Wang B; Zhou L
Ann Hepatol; 2023; 28(5):101121. PubMed ID: 37302574
[TBL] [Abstract][Full Text] [Related]
10. Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis.
Jaskowski TD; Nandakumar V; Novis CL; Palmer M; Tebo AE
Clin Chim Acta; 2023 Feb; 540():117219. PubMed ID: 36610465
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area].
Qian ZP; Mei X; Zhang YY; Zou Y; Zhang ZG; Zhu H; Guo HY; Liu Y; Ling Y; Zhang XY; Wang JF; Lu HZ
Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):229-233. PubMed ID: 32270660
[No Abstract] [Full Text] [Related]
12. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.
Itoh S; Ichida T; Yoshida T; Hayakawa A; Uchida M; Tashiro-Itoh T; Matsuda Y; Ishihara K; Asakura H
J Gastroenterol Hepatol; 1998 Mar; 13(3):257-65. PubMed ID: 9570238
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis.
Yang J; Yu YL; Jin Y; Zhang Y; Zheng CQ
World J Gastroenterol; 2016 Sep; 22(33):7579-86. PubMed ID: 27672278
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China.
Chen Q; Zhong R; Dong K; Wang Y; Kui Y; Ma B; Wen X; Jin Q
Dig Liver Dis; 2022 Aug; 54(8):1094-1100. PubMed ID: 34789400
[TBL] [Abstract][Full Text] [Related]
15. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.
Yang F; Yang Y; Wang Q; Wang Z; Miao Q; Xiao X; Wei Y; Bian Z; Sheng L; Chen X; Qiu D; Fang J; Tang R; Gershwin ME; Ma X
Aliment Pharmacol Ther; 2017 Mar; 45(5):733-743. PubMed ID: 28083929
[TBL] [Abstract][Full Text] [Related]
16. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of patients with primary biliary cirrhosis].
He L; Lai Y; Lai L; Luo K; Wang W; Tian Y; Gong G; Zhang M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 40(12):1333-9. PubMed ID: 26739075
[TBL] [Abstract][Full Text] [Related]
18. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis.
Ben Lamine Z; Ben Jazia I; Ben Ahmed M; Ben Slama A; Baccouche A; Slama F; Jemaa A; Ghedira I; Mankaï A
Arab J Gastroenterol; 2021 Dec; 22(4):316-320. PubMed ID: 34090832
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis.
Haldar D; Janmohamed A; Plant T; Davidson M; Norman H; Russell E; Serevina O; Chung K; Qamar K; Gunson B; Hansen B; Richter A; Trivedi PJ; Hirschfield GM
Liver Int; 2021 Mar; 41(3):535-544. PubMed ID: 33022821
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and impact of Sjögren's syndrome in primary biliary cholangitis: a systematic review and meta-analysis.
Deng X; Li J; Hou S; Ci B; Liu B; Xu K
Ann Hepatol; 2022; 27(6):100746. PubMed ID: 35970319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
